Astria Therapeutics, Inc.
ATXSHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$111.6M | −$83.0M | −$53.5M | −$195.0M | −$37.4M | −$27.1M |
| Net income | −$94.3M | −$72.9M | −$51.8M | −$194.9M | −$37.3M | −$6.0M |
| Total assets | $342.4M | $254.7M | $230.6M | $127.5M | $47.5M | $41.8M |
| Total liabilities | $23.1M | $11.6M | $9.4M | $5.2M | $6.8M | $6.1M |
| Equity | $319.3M | $243.1M | $221.2M | $122.3M | $40.7M | $35.7M |
| EPS (diluted) | $-1.68 | $-2.42 | $-3.55 | $-24.58 | $-12.20 | — |
| Shares out. | 54.9M | 28.0M | 13.0M | 13.0M | 17.9M | 11.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2024- Operating margin
- —
- Net margin
- —
- Return on equity
- −29.5%
- Return on assets
- −27.5%
- Return on capital (ROCE)
- −34.5%
- Liabilities / assets
- 6.7%
- Debt / equity
- 0.07×
- Book value / share
- $5.82
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2024- Altman Z″ (distress)
- 11.94safe
- Accruals / assets
- −3.8%clean
- Piotroski F-Score
- 2/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 warning● 3 good- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1Active Not Recruitingreadout ~2026-01A Study of STAR-0310 in Healthy Adult Participants
- Phase 3Recruitingreadout ~2027-03A Study of Navenibart in Participants With Hereditary Angioedema
- Phase 2Active Not Recruitingreadout ~2031-03A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema
- Phase 3Enrolling By Invitationreadout ~2031-06A Long-Term Study of Navenibart in Participants With Hereditary Angioedema
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Vestal Point Capital, LpPassive (13G)Feb 17, 2026
- Glazer Capital, LlcPassive (13G)Feb 12, 2026
- Perceptive Advisors LlcActivist (13D)Feb 9, 2026
- Magnetar Financial LlcActivist (13D)Jan 28, 2026
- Forgrowth Iii Pa B.V.Passive (13G)Nov 14, 2025
- Fmr LlcPassive (13G)Nov 7, 2025
- Integrated Core Strategies (Us) LlcPassive (13G)Oct 20, 2025
- Fairmount Funds Management LlcPassive (13G)Oct 15, 2025
- Ra Capital Management, L.P.Passive (13G)Aug 14, 2025
- Venrock Healthcare Capital Partners Iii, L.P.Passive (13G)Feb 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Violin JonathanDirector | Jan 23, 2026 | D | 263,321 | — |
| Milne Jill C.Officer — CEO and President | Jan 23, 2026 | D | 4,377 | — |
| Komjathy AndrewOfficer — Chief Commercial Officer | Jan 23, 2026 | D | 10 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| Jan 15, 2026 | 4.2M | 5.8 | -27.3% |
| Dec 31, 2025 | 5.8M | 6.7 | +37.9% |
| Dec 15, 2025 | 4.2M | 2.6 | -13.3% |
| Nov 28, 2025 | 4.8M | 4.9 | -5.4% |
| Nov 14, 2025 | 5.1M | 4.5 | +61.8% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Completed an acquisition or disposition · New financial obligation · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsJan 23, 2026
- Shareholder vote · Other material eventJan 21, 2026
- Other material eventDec 23, 2025
- Results of operationsNov 12, 2025
- Entered a material agreement · Results of operations · Other material eventOct 14, 2025
- Entered a material agreement · Regulation FD disclosure · Other material eventAug 6, 2025
- Director / officer change · Shareholder voteJun 12, 2025
- Results of operationsMar 11, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SCHEDULE 13G/AFeb 17, 2026
- SCHEDULE 13G/AFeb 12, 2026
- SCHEDULE 13D/AFeb 9, 2026
- 15-12GFeb 2, 2026
- SCHEDULE 13D/AJan 28, 2026
- EFFECTJan 27, 2026
- EFFECTJan 27, 2026
- EFFECTJan 27, 2026
- EFFECTJan 27, 2026
- EFFECTJan 27, 2026
- EFFECTJan 27, 2026
- 25-NSE/AJan 26, 2026
- S-8 POSJan 23, 2026
- S-8 POSJan 23, 2026
- S-8 POSJan 23, 2026
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.